View Clinical Trial (Medical Research Study)

A Controlled Study of Olanzapine in Children With Autism - NCT00057408-19124(Clinical Trial 115742)



ClinicalConnection.com has recently undergone an update and this page may no longer be up-to-date. Please Search For Clinical Trials to view the most current clinical trials listings.


Signup
City:  Philadelphia
State:  
PA
Zip Code: 19124
Conditions: Autistic Disorder
Purpose: This is a 12-week study which investigates the use of olanzapine to decrease disruptive behaviors sometimes associated with Autism in children, aged 3 to 12 years old. The first six weeks of the study are double-blind and placebo controlled, meaning that patients receive either placebo or olanzapine, and that neither the researchers nor the patients know whether or not they are receiving placebo or olanzapine. In the second six weeks all of the patients receive olanzapine. The purpose in using placebo is that it is otherwise impossible to know how effective the drug is or whether or not the drug causes side effects. Patients treated with placebo can have improvement and can have side effects. In the study patients receive a psychiatric evaluation, physical examination, laboratory tests, and study medication (olanzapine or placebo), free of charge.
Study summary:
Criteria: Inclusion Criteria: 1. Males and females, Aged between 3 and 12 years. 2. Autistic disorder - DSM-IV criteria. 3. A score of at least moderately impaired on the CGI-Severity item. 4. Clinical judgment that medication treatment for autism is indicated. Exclusion Criteria: 1. Rett's disorder, childhood disintegrative disorder, Asperger's disorder, and PDD, NOS. 2. Psychotic disorder (DSM-IV) (including schizophreniform disorder and schizophrenia). 3. Major depressive disorder (DSM-IV). 4. Bipolar disorder (DSM-IV). 5. History of psychoactive drug in the previous 2 weeks prior to phase 1. 6. A history of treatment with olanzapine for a cumulative period of greater than 2 weeks prior to entering phase 1. 7. Systemic diseases such as cardiac, renal, thyroid diseases, uncontrolled seizure disorder (seizure disorder that is not controlled by anti-epileptic medication - a child who is seizure free for a period of 6 months on a stable dose of antiepileptic drug would be considered controlled), or diabetes mellitus. 8. Children with a known medical cause for autistic disorder. 9. Abnormal fasting blood glucose or history of diabetes. 10. Baseline body mass index (BMI) greater than the 90th percentile for age and gender (CDC growth charts, Kuczmarski et al, 2000) (because of risk of weight gain). 11. Baseline QTc >450 msec. Note: Historically, patients we evaluate do not have QTc values >450. 12. Dyskinesias at baseline (per the criteria of Schooler and Kane, 1982).
Study is available at: Drexel University College of Medicine c/o Friends Hospital
Philadelphia, PA 19124
United States

Primary Contact:
Richard P Malone, M.D.
Email: rmalone@drexelmed.edu
Phone: 215-831-4058

Secondary Contact:
Richard P Malone, MD
Email: rmalone@drexelmed.edu
Phone: 215-831-4058
If you are interested in this clinical trial please use the contact information above. If you would like to get additional information about this clinical trial please visit ClinicalTrials.gov.
Trials Alerts: If you would like to be notified of new clinical trials as they become available please register for a free account.
Data Source: ClinicalTrials.gov
Date Processed: March 21, 2011
Modifications to
this listing:		 Only selected fields are shown, please use the link above to view all information about this clinical trial.